Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look: Investor Returns For Hospitals In Emerging Markets

This article was originally published in PharmAsia News

Executive Summary

SINGAPORE - As emerging markets grow, governments are pumping funds into upgrading hospitals and many offer incentives for foreign investment

You may also be interested in...



In Major Policy Turnaround, Chinese Premier's Office Lifts Restrictions On Foreign Investment In Hospitals

BEIJING - In a major new policy change as part of sweeping health system reforms slated to be introduced in stages through the year 2020, the Chinese premier's office, or State Council, is lowering decades-old barriers on foreign investment in and control of hospitals across the country

Middle East And North African Countries Represent New Growth Opportunities For Global Pharma Industry

After China and India, the Middle East and North African (MENA) regions could present another fast-growing opportunity for the global pharmaceutical industry. A recent launch of the first MENA-focused health fund by TVM Capital highlights the promise

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel